Rational design and biological investigation of benzylidene-substituted pyrazolo[3,4- b ]pyridine derivatives as novel PIM-1 kinase inhibitors with anticancer potential
Future Medicinal Chemistry · 2026
DOI: 10.1080/17568919.2026.2642671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Medicinal Chemistry, 2026. Verfasst von Aastha Singh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Analysis, ISF College of Pharmacy, Moga, India. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-pim-1, Antineoplastic Agents, Pyridines, Pyrazoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Taif University.
Abstract (Originalsprache)
BACKGROUND: PIM-1 kinase is a significant oncogenic serine/threonine kinase that is implicated in various aspects of cancer cell proliferation, survival, and tumor progression. In this manuscript, a novel series of benzylidene-substituted pyrazolo[3,4-b]pyridine derivatives was designed and synthesized as potential PIM-1 kinase inhibitors with anticancer activity. METHODS: The novel derivatives were synthesized by a novel synthetic route involving a three-step synthetic method from 2-chloro-3-cyanopyridine to produce a total of ten derivatives 6A-6J. The structures of the novel derivatives were confirmed by Fourier Transform Infrared Spectroscopy (FT-IR), 1H and 13C Nuclear Magnetic Resonance Spectroscopy (NMR), and Mass Spectroscopy. The anticancer activity of the novel derivatives was assessed by evaluating their inhibitory activity against the MCF-7 human breast cancer cell line by a colorimetric MTT assay. The inhibitory activity of the novel derivatives against PIM-1 kinase was assessed by an enzyme-linked immunosorbent assay. The binding mode of the most active derivatives within the PIM-1 kinase active site was assessed by molecular docking studies. RESULTS: The results from this investigation revealed that some of the novel derivatives exhibited significant anticancer activity against the MCF-7 human breast cancer cell line. The most potent derivative 6H had an IC₅₀ value of 1.43 ± 0.18 μM, while compound 6D had an IC₅₀ value of 1.56 ± 0.30 μM compared to the standard drug doxorubicin. The inhibitory activity of the most active derivatives against PIM-1 kinase was concentration-dependent. The results from the molecular docking studies revealed that compound 6H had a favorable binding mode within the PIM-1 kinase active site by hydrogen bonding and hydrophobic interactions with some amino acid residues within the enzyme's active site. CONCLUSION: The results from this investigation revealed that benzylidene-substituted pyrazolo[3,4-b]pyridine derivatives are potential anticancer agents that could be developed as potential anticancer drug candidates by inhibiting PIM-1 kinase activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Analysis, ISF College of Pharmacy, Moga, India.
- Department of Pharmacognosy, College of Pharmacy, Taif University, Taif, Saudi Arabia.
Förderung
- Taif University
Zitieren
APA
Singh, A., Maity, S., Devi, P., Ali, A., & Asati, V. (2026). Rational design and biological investigation of benzylidene-substituted pyrazolo[3,4- b ]pyridine derivatives as novel PIM-1 kinase inhibitors with anticancer potential. Future Medicinal Chemistry. https://doi.org/10.1080/17568919.2026.2642671
Vancouver
Singh A, Maity S, Devi P, Ali A, Asati V. Rational design and biological investigation of benzylidene-substituted pyrazolo[3,4- b ]pyridine derivatives as novel PIM-1 kinase inhibitors with anticancer potential. Future Medicinal Chemistry. 2026. doi:10.1080/17568919.2026.2642671
BibTeX
@article{Singh2026,
author = {Singh, Aastha and Maity, Subhadip and Devi, Priya and Ali, Abuzer and Asati, Vivek},
title = {Rational design and biological investigation of benzylidene-substituted pyrazolo[3,4- b ]pyridine derivatives as novel PIM-1 kinase inhibitors with anticancer potential},
journal = {Future Medicinal Chemistry},
year = {2026},
doi = {10.1080/17568919.2026.2642671}
}
EUVIMED